

News Release

FOR IMMEDIATE RELEASE

11 February 2010

Contact: **Neal G. Koller**
President & CEO
Board of Directors
443 994 0101

VAAN MAKES SECOND INVESTMENT IN PLUROGEN

(Charlottesville, VA, February 11, 2010) – PluroGen Therapeutics, Inc. today announced that VAAN (the Virginia Active Angel Network) made their second investment in PluroGen.

Commenting on the VAAN's second investment, Neal G. Koller, President & CEO of PluroGen, said, "This second VAAN investment in PluroGen represents a significant validation and confirmation of our progress and the value PluroGen provides as an investment vehicle. We are pleased VAAN's exhaustive due diligence process resulted in their decision to invest. They have and will continue to be an appreciated active investor and help to the company."

VAAN released today the following statement on their second investment in PluroGen:

“Virginia Active Angel Network, LLC has completed its portion of a \$1.0 M Series A Preferred round today in Plurogen Therapeutics, Inc., a novel skin care & wound healing company w/ gel technologies.

VAAN invested an additional round in its portfolio company, Plurogen Therapeutics, Inc., a UVA-patented company. VAAN conducted a top-to-bottom full due diligence on PTI as the original investment was made two years ago. In Q3, 2009, PTI has 2 successful in-human use trials for its PluroGel® with Silver Sulfadiazine in Europe, became post-revenue, and received another NIH grant for \$100K to study its PluroGel gel technology, including its Chitosan gel technology along with other technologies in the spray application of fat-derived stem cells for wound healing. VAAN's original investment was a convertible note which auto-converted, and therefore this is a Series A round that matches that conversion price. Feb. 11, 2009, www.plurogen.com. Contact Neal Koller if you have an interest in this round, or the next at nkoller@plurogen.com. Contact Letitia Green if you have an interest sufficient to need the due diligence report. Over 20 physicians are invested in this project separate from VAAN.”

About PluroGen Therapeutics, Inc.

PluroGen is a burn, wound and skin care company commercializing our multiple patent-protected technology platforms, the 1st of which is our core gel technology that provides superior and differentiated physical, bio-impact and multi-function benefits. Our multiple technology platforms are configurable to deliver a wide variety of medicinal and beneficial compounds as protected and advanced therapeutic and topical products for simple and complex skin care and burn and wound healing. PluroGen's product pipeline targets improved, protected therapies for the 6 areas of treatment in tissue management and healing (cleansing, infection, pain, inflammation, tissue salvage, tissue regeneration).

PluroGen's first gels, PluroGel® and ActiGel™, are being used initially in skin and wound cleansing products, for personal skin care products and for two branded topical antimicrobial products, PluroGel® Barrier Gels and PluroGel® Barrier Dressings. PluroGel® / ActiGel™ technology is currently in routine use at the University of Virginia Medical Center, having shown superior results on more than 2,000 patients in two different patient populations, severe burns and chronic wounds. The PluroGen management and operational teams, Boards and Principal Investigators are recognized global clinical and commercial leaders in PluroGen's target markets of burn and wound care and in the life sciences industry.

For more information about PluroGen Therapeutics, Inc., visit the Company's web site at www.plurogen.com.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company's reports filed with the U.S. Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or otherwise.